Entyvio is indicated for patients who have had an inadequate response to, lost response to, or are intolerant of, either conventional therapy or a tumour necrosis factor antagonist.
The recommendation by NICE states that vedolizumab should be discontinued if it stops working or surgery is required.
An assessment should take place every 12 months to determine whether treatment should be continued. Patients who are in complete remission at 12 months can stop treatment and restart later if symptoms return.
Approval for NHS use was granted on the condition that the company provides vedolizumab with the discount agreed in the patient access scheme.
NICE technology appraisal TA342
Vedolizumab is a humanised monoclonal antibody that acts specifically in the gut. It targets α4β7 integrin, which is responsible for the recruitment of white blood cells to inflamed bowel tissue.
The most common adverse effects of vedolizumab are nasopharyngitis, headache and joint pain.